Back to News
Market Impact: 0.2
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Source: GlobeNewswire
Healthcare & BiotechPandemic & Health Events
Health Canada authorized a clinical trial evaluating the efficacy and safety of two MDMA-assisted therapy sessions in up to 100 veterans and frontline workers. The study is a constructive regulatory and clinical-development milestone, but it provides no efficacy results or commercial financial impact yet.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- ‘Like Kashmir’: How a toxic marble dump yard became a tourist spot in India
- Swiss firms plan to expand China investments as trade deal deepens ties
- Gaza doctors struggle with bereavement, overwork, trauma amid genocidal war
- OmniAb: A Self-Funding Option Book On 433 Partner Programs
- Regeneron: 3 Key Takeaways for Long-Term Investors
- AbbVie: 3 Key Takeaways for Long-Term Investors